vTv Therapeutics (FRA:5VT0) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is vTv Therapeutics LT-Debt-to-Total-Asset?

vTv Therapeutics FRA:5VT0 +3.21% 35 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €7,190.85.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. vTv Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

vTv Therapeutics's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

vTv Therapeutics (FRA:5VT0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

vTv Therapeutics LT-Debt-to-Total-Asset Related Terms

vTv Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics LT-Debt-to-Total-Asset Chart

vTv Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.02

0.00

vTv Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

35GF Score

vTv Therapeutics Inc FRA:5VT0

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

vTv Therapeutics LT-Debt-to-Total-Asset Calculation

vTv Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	76.774
	=

vTv Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	85.473
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

vTv Therapeutics (FRA:5VT0) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on vTv Therapeutics and its competitors.

Is vTv Therapeutics' LT-Debt-to-Total-Asset too high?

vTv Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does vTv Therapeutics' LT-Debt-to-Total-Asset compare to SMNR and CNTB?

vTv Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is vTv Therapeutics stock overvalued right now?

vTv Therapeutics (FRA:5VT0) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is €7,190.85, compared to a current price of €32.20 — trading 99.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €32.20 is trading 99.6% below its estimated GF Value™ of €7,190.85.

Key valuation signals for FRA:5VT0:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €7,190.85 vs. price of €32.20 (99.6% below fair value)
GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SMNR CNTB ENLV MENS SPRO VXRT ACOG HURA ADCT GNLX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges VTVT:USA

Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265

Website https://www.vtvtherapeutics.com

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

35GF Score

Get the complete analysis for FRA:5VT0

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.20

Price

€7,190.85

GF Value

View FRA:5VT0 Analysis

See LT-Debt-to-Total-Asset data for all stocks →